Brought to you by 
Amgen gets rights to Kyowa's KW0761 for inflammation; terminated
16 Nov 2021
Executive Summary
Amgen has licensed exclusive global development and marketing rights to Kyowa Hakko Kogyo's (in the process of merging with Kirin) KW0761 humanized monoclonal antibody. The deal excludes Japan, Korea, China, and Taiwan.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen gets rights to Kyowa's KW0761 for inflammation; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice